The democratic life of pharmaceutical companies will focus on innovation and development.
Release time:
2020-07-22
Pharmaceutical Company's Democratic Life Meeting Focuses on Innovation and Development
News 4# July 18 Morning, Pharmaceutical Company held a democratic life meeting of its management team.
Before the democratic life meeting was held, the pharmaceutical company made careful preparations and held symposiums with representatives of functional departments and subordinate enterprises respectively to collect opinions and suggestions on the pharmaceutical company and team members 20 . Staff representatives put forward a lot of insights from production, operation, staff life, enterprise party building and other aspects, laying the foundation for a good democratic life meeting.
The members of the participating team strengthened the armed forces of innovation theory around ", built up 'four consciousnesses ' , strengthened ' four self-confidence ' , resolutely achieved 'two maintenance ' , and had the courage to act, with a truth-seeking and pragmatic style, we will resolutely implement the Party Central Committee's decision-making and deployment to the theme of " , insist on putting the enterprise in, putting responsibilities in, and putting ourselves in, from the three aspects of ideology and politics, mental state, and work style. In all aspects, seek truth from facts to investigate problems, trace the source and analyze the causes, frankly and seriously carry out criticism, and closely follow the problems to propose improvement measures, the purpose of exchanging ideas, enhancing unity, and improving together was achieved, and a high-quality and effective democratic life meeting was held. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, took the lead, and each team member frankly pointed out the shortcomings of others, achieving the goal of helping each other and making common progress. The
meeting stressed that the convening of the democratic life meeting has laid a solid ideological foundation for strengthening the team's own construction, uniting the overall joint force of the team, and doing a good job in the future work. In the next step, the pharmaceutical company will continue to earnestly study and understand Xi Jinping's new era of socialism with Chinese characteristics, adhere to "four self-confidence " , strengthen "four consciousness " , remember "two maintenance " , further strengthen ideals and beliefs, unify ideological understanding, and formulate rectification and implementation plans, focus on the outstanding problems found out at the meeting, implement the responsibility for rectification, comprehensively promote the implementation of problem rectification, and further improve innovative thinking, strengthen enterprise research, keep close contact with the masses, ensure that democratic life will achieve tangible results, and promote the pharmaceutical industry The company achieves high-quality development. Qin Xuping, member of the Party Committee of
Group Company and Director of the Party and Mass Work Department, attended the meeting. He fully affirmed the democratic life of the pharmaceutical company's management team, and hoped that the pharmaceutical company's management team would pay more attention to learning and innovation, and further strengthen party building Work to promote production and operation to a new level. (This correspondent)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page